What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Recombinant anti-CD3 immunotoxin fusion protein composed of bivalent UCHT1 single-chain variable fragments linked to a modified diphtheria toxin (A-dmDT390). VG712 is administered intravenously to selectively deplete CD3-positive T cells.”In the company’s words, NCT07529405 on ClinicalTrials.gov
- Tested for
- Mycosis Fungoides
- Main trialPhase 2
- “VG712 (A-dmDT390-bisFv(UCHT1) fusion protein) is a recombinant anti-CD3 immunotoxin that selectively depletes CD3-positive T cells through irreversible inhibition of protein synthesis. This Phase II study (CurbMF-001) evaluates the safety and efficacy of VG712 compared with mogamulizumab in subjects with relapsed or refractory mycosis fungoides (MF) who have failed 2 or more prior systemic therapies. The study has two parts: a lead-in dosing part (BOIN design, up to 24 subjects) to determine RP2D, followed by a randomized part (approximately 322 subjects, 1:1 VG712 vs. mogamulizumab).…”In the company’s words, NCT07529405 on ClinicalTrials.gov
Other drugs for Mycosis Fungoides
- PTX-100Prescient Therapeutics, Ltd. · Phase 2
- MDSY-1240Medsyn Biopharma, LLC · Phase 1/2
- GolcadomideCelgene · Phase 1/2
- FenretinideSciTech Development, Inc. · Phase 1
- DuvelisibSecuraBio · Phase 1
- KK2223Kyowa Kirin, Inc. · Phase 1
Coming up1
- 30 Dec 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Dec 2030 | A Study of VG712 in Patients With Mycosis Fungoides |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026